5,6,7,8-tetrahydro-9-(2-hydroxy-1-ethyl)-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole | 157014-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5,6,7,8-tetrahydro-9-(2-hydroxy-1-ethyl)-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole
• 英文别名: 5,6,7,8-tetrahydro-9-(2-hydroxyethyl)-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole；9-(2-hydroxyethyl)-2,4-di-1-pyrrolidinyl-5,6,7,8-tetrahydro-9H-pyrimido[4,5-b]indole；2-[2,4-Di(pyrrolidin-1-yl)-5,6,7,8-tetrahydro-9H-pyrimido[4,5-b]indol-9-yl]ethan-1-ol；2-(2,4-dipyrrolidin-1-yl-5,6,7,8-tetrahydropyrimido[4,5-b]indol-9-yl)ethanol
• CAS: 157014-39-6
• 化学式: C₂₀H₂₉N₅O
• 分子量: 355.483
• InChiKey: SQCGVLUYMJYAKN-UHFFFAOYSA-N

物化性质

• 沸点：
  620.2±65.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  57.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5,6,7,8-tetrahydro-9-(2-hydroxy-1-ethyl)-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole 在 草酰氯 、 5%-palladium/activated carbon 、 氢气 、 二甲基亚砜 作用下， 以 四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 、 水 为溶剂， 反应 24.33h， 生成 2-(2,4-Dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)acetic acid
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p
• 作为产物：
  描述：

  2,4-di(1-pyrrolidinyl)-6-chloropyrimidine 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 114.0h， 生成 5,6,7,8-tetrahydro-9-(2-hydroxy-1-ethyl)-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p

文献信息

• Pharmaceutically active bicyclic-heterocyclic amines
  申请人：The Upjohn Company

  公开号：US05502187A1

  公开（公告）日：1996-03-26

  The pharmaceutically active bicyclic heterocyclic amines (XXX) ##STR1## where W.sub.1 is --N.dbd. or --CH.dbd.; W.sub.3 is --N.dbd. or --CH.dbd.; W.sub.5 is --N.dbd. or --CR.sub.5 -- with the proviso that W.sub.5 is --CR.sub.5 -- when both W.sub.1 and W.sub.3 are --N.dbd. which are useful as pharmaceuticals in treating mild and/or moderate to severe head injury, subarachnoid hemorrhage and subsequent ischemic stroke, asthma and reduction of mucous formation/secretion in the lung and other diseases and injuries.

  具有药用活性的双环杂环胺类化合物（XXX）##STR1##其中W.sub.1为--N.dbd.或--CH.dbd.; W.sub.3为--N.dbd.或--CH.dbd.; W.sub.5为--N.dbd.或--CR.sub.5--，但W.sub.5为--CR.sub.5--当W.sub.1和W.sub.3均为--N.dbd.，这些化合物在治疗轻度和/或中度至重度头部损伤、蛛网膜下腔出血和随后的缺血性中风、哮喘以及减少肺部粘液形成/分泌和其他疾病和损伤中具有药用价值。
• Pyrimido\x9b4,5-B!indoles
  申请人：Pharmacia & Upjohn Company

  公开号：US05795986A1

  公开（公告）日：1998-08-18

  The pyrimido\x9b4,5-b!indoles (I) ##STR1## and lactams (XIII) of the invention are useful as pharmaceutical agents for a number of different indications.

  这个句子的中文翻译如下： 该发明中的嘧啶并[4,5-b]吲哚(I) ## STR1 ## 和内酰胺(XIII)可用作多种不同指示的医药制剂。
• Organic Process Research and Development. 2001, 5, 144-151
  作者：

  DOI：——

  日期：——
• US5502187A
  申请人：——

  公开号：US5502187A

  公开（公告）日：1996-03-26
• Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A
  作者：Gordon L. Bundy、Lee S. Banitt、Paul J. Dobrowolski、John R. Palmer、Theresa M. Schwartz、David C. Zimmermann、Michael F. Lipton、Michael A. Mauragis、Michael F. Veley、Robert B. Appell、Robert C. Clouse、Edward D. Daugs

  DOI：10.1021/op000221p

  日期：2001.3.1

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.